Vik Vaz.

On the day Pleno Inc. announced it had closed a $25 million Series B, it also announced who would spend it. Vik Vaz walked into the CEO's office in December 2024 with no settling-in period - the funding and the appointment landed the same morning. The San Diego biotech wanted someone who could turn a science project into a product line, and Vaz had spent twenty years collecting exactly the credentials for it.

Most biotech founders arrive from one direction. Vaz arrived from three. He is an actively licensed physician who trained as a surgeon and an interventional oncologist. He was a partner at McKinsey & Company and, separately, at Boston Consulting Group - two firms that rarely share an alumnus at that level. And he ran strategy, market intelligence, and the companion-diagnostics business at Illumina, the company that did more than any other to make genome sequencing cheap.

Put those together and you get a rare profile: a leader who can read a clinical study from the vantage point of the person who once performed the procedure behind it, then model the market for it, then build the commercial machine to sell it. That is the job at Pleno, and it is why the board handed him the keys at the moment the money cleared.

The product is called RAPTOR. The method behind it is called Hypercoding. The promise is deceptively plain: detect DNA, RNA, and protein targets from a single sample, quickly, and cheaply enough that the test stops being exotic. Vaz's task is to make that promise ordinary.

For most of modern biology, you picked your question and then picked your instrument. Want to read DNA? One workflow. Want to measure RNA expression? Another. Want to quantify proteins? A different machine again, with its own reagents, its own technicians, its own afternoon. Each answer arrived separately, and stitching them back together into a picture of what a cell or a tumor is actually doing was slow and expensive.

Multi-omics is the refusal to accept that division. The word means looking at several layers of biology at once - the genome, the transcriptome, the proteome - and reading them as one story rather than three. Pleno's argument is that the most useful biological signal lives in the overlap, in seeing how DNA, RNA, and protein move together in a single specimen. The RAPTOR platform is built to capture that overlap in one pass.

The harder problem is not detection. It is detection that anyone can afford. Plenty of impressive instruments exist that only a handful of elite labs will ever buy. Pleno frames its mission around accessibility and affordability, which is a commercial statement as much as a scientific one. It is also, not coincidentally, the exact problem Vaz spent his Illumina years thinking about - how a powerful test stops being a luxury and becomes a routine line item on a lab order.

That framing explains the choice of CEO. A company chasing a Nobel would hire a different person. A company trying to turn a known-target detection method into a sellable, scalable product hires the surgeon who became a strategist who ran a diagnostics business. Vaz is the answer to the question Pleno is actually asking.

Start with the hands. Vaz trained as a surgeon and clinical instructor at Harvard Medical School's Beth Israel Deaconess Medical Center, then specialized in radiology and interventional oncology at the University of Miami. Interventional oncology is the work of treating cancer through tiny incisions and image guidance - precise, high-stakes, and unforgiving of error. It is a discipline that teaches you to respect what the data is actually telling you, because a patient is on the table.

Then came the pivot to strategy. As a partner at McKinsey and later at BCG, Vaz advised pharmaceutical, medical-device, and life-sciences leaders on growth, transformations, turnarounds, and transactions. The clinician learned to think in markets, portfolios, and deal structures - the second language a science company needs from its CEO.

At Illumina he put both to work. As head of strategy and market intelligence, and leader of the companion-diagnostics business, he handled enterprise-wide planning, portfolio investment, strategic partnerships, new-market development, and revenue for the diagnostics assays that tell doctors which patients a given drug will help. Companion diagnostics is the seam where the lab result meets the prescription, and running it means living at the intersection of science, regulation, and commerce.

Pleno is the synthesis. The company calls its mission making complex multi-omic, known-target detection accessible and affordable. Vaz's whole resume is a study in that exact translation problem - taking something technically remarkable and making it usable, payable, and ordinary. The RAPTOR launch, including an early commercial agreement with Utah-based Slopes Bio, is the first public test of whether the synthesis holds.

The $25 million Series B that arrived with Vaz was not a token round. Pleno has raised roughly $80 million in total, and the latest tranche drew names that crossatlantic life-sciences investors recognize: Deerfield Management, Foresite Capital, and Medical Excellence Capital. These are firms that write checks into the gap between a promising instrument and a commercial product - precisely the gap Pleno was sitting in when it changed CEOs.

Pleno also came up through EvoNexus, the San Diego technology incubator, and sits in the dense cluster of genomics and diagnostics companies that ring the city's Torrey Pines mesa. San Diego is the right zip code for this work; it is where Illumina itself grew up, and the talent and capital both understand the long, capital-hungry arc of a sequencing-adjacent company.

The structure of the appointment matters too. Vaz did not just take the CEO title; he joined the board. That signals a mandate to set direction, not just execute someone else's plan. The investors backing a commercial launch generally want an operator who can be held accountable for revenue, and they got one with a track record of running a diagnostics P&L at scale.

Pleno's reported headcount sits around forty people. That is small enough to move fast and large enough to ship something real - the awkward, thrilling size where a single hire at the top can redirect the whole company. The Series B buys runway; Vaz is meant to spend it converting the RAPTOR platform from demonstration into deployment.

Commercial launch is the part of biotech that breaks people. The science can be sound, the demo can dazzle, and the company can still stall on the unglamorous work of pricing, support, regulatory positioning, and convincing a skeptical lab director to change a workflow that already works. This is the stretch Vaz was hired for, and his whole career reads like preparation for it. He ran the diagnostics business that lives or dies on adoption. He advised the companies trying to make these transitions. He treated the patients on the receiving end.

His stated ambition for Pleno is unflashy by design: make complex multi-omic, known-target detection accessible and affordable, and push it into real applications across oncology and infectious disease. There is no talk of disrupting biology itself, only of making a hard measurement ordinary. It is the kind of goal that sounds modest until you remember how much of medicine is gated behind tests that are too slow, too costly, or too rare to order casually.

The early signal is the commercial agreement with Slopes Bio - a first customer is worth more than a thousand slides. Whether RAPTOR becomes a fixture or a footnote depends on the next stretch, and that is now Vaz's story to write. Catch him mid-stride: the surgeon who learned to think in markets, holding a freshly closed round and a machine that promises to read the whole molecular story at once.